Latest News for: chugai

Edit

Corporate Governance Report [PDF 1MB] (Chugai Pharmaceutical Co Ltd)

Public Technologies 24 Dec 2025
Please note that the following is an unofficial English translation of the Japanese original text of the Corporate Governance Report of CHUGAI PHARMACEUTICAL CO., LTD. (“Chugai” or the “Company”), which is reported to the Tokyo Stock Exchange.
Edit

Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron (Chugai Pharmaceutical Co Ltd)

Public Technologies 18 Dec 2025
). December 18, 2025 ... Chugai Pharmaceutical Co., Ltd ... TOKYO, December 18, 2025 -- Chugai Pharmaceutical Co., Ltd ... Orforglipron was discovered by Chugai, and Eli Lilly holds its exclusive development and commercialization rights ... Chugai Pharmaceutical Co.
Edit

Chugai Awarded Highest A-Ratings by CDP in Climate Change and Water Security (Chugai Pharmaceutical Co Ltd)

Public Technologies 17 Dec 2025
Chugai Awarded Highest A-Ratings by CDP in Climate Change and Water Security. fiOKYO, Dcccmdcr !7, 2025 -- Chugai Wharmaccu"icai Co., W"d ... Chugai's Sus"ainadiii"y. ... Chugai Pharmaceutical Co.
Edit

Chugai Opens U.S. Partnering Office in South San Francisco to Accelerate Global Open Innovation (Chugai Pharmaceutical Co Ltd)

Public Technologies 11 Dec 2025
Chugai Opens U.S ... With the establishment of Chugai Partnering US Office, Chugai will further strengthen this global partnering network and establish a comprehensive framework for worldwide partnership activities ... Chugai Partnering US Office.
Edit

Roche’s Announcement Regarding Giredestrant (Presentation of Latest Data in Estrogen Receptor Positive Breast Cancer at SABCS) (Chugai Pharmaceutical Co Ltd)

Public Technologies 11 Dec 2025
). News Release. Roche's Announcement Regarding Giredestrant (Presentation of Latest Data in Estrogen Receptor Positive Breast. Cancer at SABCS). TOKYO, December 11, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO ... Disclaimer. Chugai Pharmaceutical Co. Ltd.
Edit

48-Week Phase III Results Presented at Japanese Retina and Vitreous Society Meeting Show that Vabysmo Sustained Vision Improvements in Japanese Patients with Angioid Streaks (Chugai Pharmaceutical Co Ltd)

Public Technologies 08 Dec 2025
TOKYO, December 8, 2025 -- Chugai Pharmaceutical Co., Ltd ... Chugai Files ... https.//www.chugai-pharm.co.jp/english/news/detail/20250417122000_1150.html About the NIHONBASHI study ... Chugai Pharmaceutical Co.
Edit

Renalys Pharma’s Announcement Regarding Sparsentan (Results of Domestic Phase III Study for IgA Nephropathy) (Chugai Pharmaceutical Co Ltd)

Public Technologies 26 Nov 2025
TOKYO, November 26, 2025 -- Chugai Pharmaceutical Co., Ltd ... (hereinafter "Renalys Pharma"), which Chugai is scheduled to acquire as a wholly-owned subsidiary on ... Chugai Pharmaceutical Co.
Edit

Port Delivery System with Ranibizumab Demonstrates Results Phase I/II Trial for Neovascular Age-related Macular Degeneration and Diabetic Macular Edema in Japan (Chugai Pharmaceutical Co Ltd)

Public Technologies 25 Nov 2025
TOKYO, November 25, 2025 -- Chugai Pharmaceutical Co., Ltd ... Osamu Okuda, Chugai's President and CEO. Chugai will file a new drug application in Japan based on the study results, ... Chugai Pharmaceutical Co.
Edit

Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for Repotrectinib with NTRK Fusion-Positive Solid-Tumors (Chugai Pharmaceutical Co Ltd)

Public Technologies 20 Nov 2025
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for Repotrectinib with NTRK Fusion-Positive Solid-Tumors ... TOKYO,November 20, 2025 -- Chugai Pharmaceutical Co., Ltd ... Chugai Pharmaceutical Co.
Edit

Anti-Cancer Agent/Humanized Anti-CD20 Monoclonal Antibody Gazyva, Now Available for Use in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia (Chugai Pharmaceutical Co Ltd)

Public Technologies 20 Nov 2025
Chugai Pharmaceutical Co., Ltd ... TOKYO, November 20, 2025 -- Chugai Pharmaceutical Co., Ltd ... Chugai and Nippon Shinyaku jointly develop and market the product in Japan.About Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL).
Edit

Roche’s Announcement Regarding giredestrant (Announcement of Phase III lidERA Study Results) (Chugai Pharmaceutical Co Ltd)

Public Technologies 19 Nov 2025
). News Release. Roche's Announcement Regarding giredestrant (Announcement of Phase III lidERA Study Results). TOKYO, November 19, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO ... The study met its primary endpoint ... Disclaimer. Chugai Pharmaceutical Co. Ltd.
Edit

Roche Announces Global Phase III INShore Study Topline Results on Gazyva for Idiopathic Nephrotic Syndrome in Children and Young Adults (Chugai Pharmaceutical Co Ltd)

Public Technologies 30 Oct 2025
). Chugai Pharmaceutical Co., Ltd. Nippon Shinyaku Co., Ltd ... TOKYO, October 30, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO. 4519) and Nippon Shinyaku Co., Ltd. (TOKYO ... Contacts. Chugai Pharmaceutical Co., Ltd ... +81-(0)3-3273-0881 ... Chugai Pharmaceutical Co.
Edit

Notice Regarding the Purchase of Treasury Stock in Connection with the Treatment of Fractions of Shares Resulting from a Stock Consolidation （105KB） (Chugai Mining Co Ltd)

Public Technologies 27 Oct 2025
). October 24, 2025. Listed Company Name. Chugai Mining Co., Ltd. (Stock code no.. 1491, Tokyo Stock Exchange Standard Market) Representative. Takeo NISHIMOTO, CEO and President. For Inquiry. Isao SAKURABA, IR Center (Telephone ... 2,363 shares ... Chugai Mining Co.
Edit

Renalys Pharma to be Acquired by Chugai Pharmaceutical

The Eagle-Tribune 24 Oct 2025
... BT Slingsby; "Renalys") and Chugai Pharmaceutical Co., Ltd.
Edit

Q3 Results (Jan-Sep 2025) [PDF 994KB] (Chugai Pharmaceutical Co Ltd)

Public Technologies 24 Oct 2025
Chugai Pharmaceutical Co., Ltd ... 4519 (URL https.//www.chugai-pharm.co.jp/english) Representative ... Net income attributable to Chugai shareholders ... Equity attributable to Chugai shareholders. Ratio of equity attributable to Chugai shareholders.

Article Search

tools
×
×
×
×